CastleVax | sciencenewsnet.in

Breaking News

Three Johns Hopkins Medicine Researchers Named Fellows of the American Association for the Advancement of Science

Glaucoma Research Foundation establishes Strategic Advisory Council

1 in 5 milk samples from grocery stores test positive for bird flu. Why the FDA says it’s still safe to drink

‘Fallout’ success: video game nostalgia spans multiple media, explains expert

Scientists are shaking up lithium extraction with a different kind of chemistry

ORNL’s Curran named Fellow of SAE, ASME

Computer Scientists Unveil Novel Attacks on Cybersecurity

Interplay between mesenchymal stem cells and macrophages: Promoting bone tissue repair

Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19

Biological scaffold as potential platforms for stem cells: Current development and applications in wound healing

29 Apr, 2024

CastleVax Inc. Receives BARDA Project NextGen Award Valued at up to $338 Million to Advance Intranasal NDV-based COVID-19 Booster Vaccine into Phase 2b Clinical Efficacy Testing

October 17, 2023 sarah JonasAnnouncement

CastleVax, a clinical stage vaccine platform company, has received a Project NexGen award valued at up to $338 million from the Biomedical Advanced Research and Development Authority (BARDA), to support the development of a next-generation, booster vaccine to protect against COVID-19 for years to come.

Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission

July 20, 2023 sarah JonasAnnouncement

The Icahn School of Medicine at Mount Sinai in New York, NY is pleased to announce that CastleVax, Inc. has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.